
THIS CIRCULAR IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION

If you are in any doubt as to any aspect of this supplemental circular or as to the action to be taken, you should consult your stockbroker or other registered dealer in securities, bank manager, solicitor, professional accountant or other professional adviser.

If you have sold or transferred all your shares in Town Health International Medical Group Limited (“Company”), you should at once hand this supplemental circular and the accompanying revised form of proxy to the purchaser, the transferee or to the bank, stockbroker or other agent through whom the sale or transfer was effected for transmission to the purchaser or the transferee.

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this supplemental circular, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this supplemental circular.



Town Health International Medical Group Limited
康健國際醫療集團有限公司

(Incorporated in the Cayman Islands and continued in Bermuda with limited liability)

(Stock Code: 3886)

SUPPLEMENTAL CIRCULAR
OF ANNUAL GENERAL MEETING REGARDING
PROPOSED APPOINTMENT OF THE NOMINATED DIRECTORS AND
SUPPLEMENTAL NOTICE OF ANNUAL GENERAL MEETING

This supplemental circular should be read together with the circular of the Company dated 17 May 2024.

A supplemental notice of the annual general meeting of the Company to be held at 11:30 a.m. on Wednesday, 12 June 2024 at 1st Floor, Town Health Technology Centre, 10-12 Yuen Shun Circuit, Siu Lek Yuen, Shatin, New Territories, Hong Kong is set out on pages 12 to 14 of this supplemental circular. A revised form of proxy for use at the annual general meeting is enclosed with this supplemental circular. Such revised form of proxy is also published on the websites of The Stock Exchange of Hong Kong Limited (<http://www.hkexnews.hk>) and the Company (<http://www.townhealth.com>).

Whether or not you are able to attend the meeting, you are requested to complete and return the enclosed revised form of proxy in accordance with the instructions printed thereon by 11:30 a.m. on Monday, 10 June 2024 or not less than 48 hours before the time appointed for holding the adjourned meeting to the office of the Company’s branch share registrar and transfer office in Hong Kong, Tricor Tengis Limited at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong. Completion and return of the revised form of proxy will not preclude you from attending and voting in person at the meeting or any adjournment thereof should you so wish, and in such event the instrument appointing a proxy shall be deemed to be revoked.

28 May 2024

CONTENTS

	<i>Page</i>
Definitions	1
Letter from the Board	3
Appendix – Biographical details of the Nominated Directors	7
Supplemental Notice of Annual General Meeting	12

DEFINITIONS

In this supplemental circular, unless otherwise defined or the context otherwise requires, the following expressions have the following meanings:

“AGM”	the annual general meeting of the Company convened to be held at 11:30 a.m. on Wednesday, 12 June 2024 at 1st Floor, Town Health Technology Centre, 10-12 Yuen Shun Circuit, Siu Lek Yuen, Shatin, New Territories, Hong Kong, the supplemental notice of which is set out on pages 12 to 14 of this supplemental circular, or any adjournment thereof
“Board”	the board of Directors
“Bye-laws”	the bye-laws of the Company
“Company”	Town Health International Medical Group Limited, a company incorporated in the Cayman Islands and continued in Bermuda with limited liability whose Shares are listed on the Main Board of the Stock Exchange
“Director(s)”	director(s) of the Company
“Group”	the Company and its subsidiaries
“Hong Kong”	the Hong Kong Special Administrative Region of the People’s Republic of China
“Listing Rules”	the Rules Governing the Listing of Securities on the Stock Exchange
“Mr. Chau”	Mr. Chau Kai Wing, a Shareholder as at the date of deposit of the Nomination Notice
“Nominated Directors”	collectively, Dr. Wong Chi Kit Nelson, Ms. Yao Yuan and Mr. Kong Peng
“Nomination Notice”	the nomination notice dated 24 May 2024 issued by Mr. Chau Kai Wing, nominating Dr. Wong Chi Kit Nelson, Ms. Yao Yuan and Mr. Kong Peng to be elected as Directors
“Original Circular”	the circular of the Company dated 17 May 2024 relating to the AGM

DEFINITIONS

“Share(s)”	ordinary share(s) of HK\$0.01 each in the share capital of the Company
“Shareholder(s)”	holder(s) of the Share(s)
“Stock Exchange”	The Stock Exchange of Hong Kong Limited
“%”	per cent.

References to time and dates in this supplemental circular are to Hong Kong time and dates.

LETTER FROM THE BOARD



Town Health International Medical Group Limited 康健國際醫療集團有限公司

(Incorporated in the Cayman Islands and continued in Bermuda with limited liability)

(Stock Code: 3886)

Executive Directors:

Mr. Choi Ka Tsan Karson *(Chairman and
Chief Executive Officer)*
Dr. Fok Siu Wing Dominic
Ms. Zhang Xiaoxue
Mr. Liu Shiyin

Non-executive Directors:

Ms. Lee Wai Ling Linda
Ms. Lau Suk Hing Clara
Mr. Liu Yang
Ms. Zhang Leidi

Independent non-executive Directors:

Mr. Yu Xuezhong
Dr. Xu Weiguo
Mr. Han Wenxin
Mr. Chan Wai Kan
Mr. Cheung Ka Ming
Mr. Tsui Wing Cheong Sammy

Registered office:

Clarendon House
2 Church Street
Hamilton HM 11
Bermuda

*Head Office and principal place
of business in Hong Kong:*

6th Floor
Town Health Technology Centre
10-12 Yuen Shun Circuit
Siu Lek Yuen
Shatin, New Territories
Hong Kong

28 May 2024

To the Shareholders

Dear Sir or Madam,

SUPPLEMENTAL CIRCULAR OF ANNUAL GENERAL MEETING REGARDING PROPOSED APPOINTMENT OF THE NOMINATED DIRECTORS AND SUPPLEMENTAL NOTICE OF ANNUAL GENERAL MEETING

1. INTRODUCTION

Reference is made to the Original Circular dated 17 May 2024.

Subsequent to the Company's despatch of the Original Circular, the Company received the Nomination Notice.

LETTER FROM THE BOARD

This supplemental circular is issued in compliance with Rule 13.70 of the Listing Rules and is to provide you with information in respect of the resolutions to be proposed at the AGM for the appointment of the Nominated Directors as Directors and to give you the supplemental notice of the AGM at which the resolutions will be proposed to consider and, if thought fit, approve such matter.

2. PROPOSED APPOINTMENT OF THE NOMINATED DIRECTORS

Subsequent to the Company's despatch of the Original Circular, the Company received the Nomination Notice from a Shareholder pursuant to which notice Dr. Wong Chi Kit Nelson, Ms. Yao Yuan and Mr. Kong Peng were nominated to stand for election as Directors at the AGM.

Accordingly, resolutions in relation to the appointment of the Nominated Directors as Directors will be proposed at the AGM in accordance with Bye-law 103 of the Bye-laws. Pursuant to Rule 13.74 of the Listing Rules, a listed issuer shall disclose the details required under Rule 13.51(2) of the Listing Rules of any directors proposed to be re-elected or proposed new director in the notice or accompanying circular to its shareholders of the relevant general meeting, if such re-election or appointment is subject to shareholders' approval at that relevant general meeting. The biographical details of the Nominated Directors are set out in the Appendix to this supplemental circular. The biographical details of Dr. Wong Chi Kit Nelson, Ms. Yao Yuan and Mr. Kong Peng as set out in the Appendix to this supplemental circular have been reproduced from the Nomination Notice and are solely based upon the information provided by Dr. Wong Chi Kit Nelson, Ms. Yao Yuan and Mr. Kong Peng in the Nomination Notice, and has not been independently verified by the Company or the Board.

Shareholders should note that the biographical details of Dr. Wong Chi Kit Nelson, Ms. Yao Yuan and Mr. Kong Peng as set out in the Appendix to this supplemental circular have been reproduced from the Nomination Notice. The Board has not verified the biographical details of the Nominated Directors as set out in the Appendix to this supplemental circular. Accordingly, no recommendation has been made by the Board or the nomination committee of the Board with regard to the proposed appointment of the Nominated Directors as Directors. Further, the Board is not in a position to comment on whether there is any matter regarding the proposed appointment of the Nominated Directors as Directors that needs to be brought to the attention of the Shareholders pursuant to Rule 13.51(2) of the Listing Rules in relation to the Nominated Directors.

The proposed appointment of the Nominated Directors as Directors is subject to the approval of the Shareholders by way of ordinary resolutions at the AGM.

LETTER FROM THE BOARD

3. AGM

The supplemental notice of AGM is set out on pages 12 to 14 of this supplemental circular.

A revised form of proxy for use at the AGM is enclosed with this supplemental circular and such revised form of proxy is also published on the respective websites of the Stock Exchange (<http://www.hkexnews.hk>) and the Company (<http://www.townhealth.com>).

Whether or not you are able to attend the AGM, you are requested to complete and return the enclosed revised form of proxy in accordance with the instructions printed thereon by 11:30 a.m. on Monday, 10 June 2024 or not less than 48 hours before the time appointed for holding the adjourned AGM (“**Closing Time**”) to the office of the Company’s branch share registrar and transfer office in Hong Kong, Tricor Tengis Limited at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong. Completion and return of the revised form of proxy will not preclude you from attending and voting in person at the AGM or any adjournment thereof should you so wish, and in such event the instrument appointing a proxy shall be deemed to be revoked.

If a Shareholder has not yet returned the original form of proxy which was despatched to the Shareholders on 17 May 2024 (“**Original Form of Proxy**”) in accordance with the instructions printed thereon, and wishes to appoint a proxy to attend the AGM on his/her/its behalf, he/she/it is required to submit the revised form of proxy. In this case, the Shareholder shall not submit the Original Form of Proxy.

If a Shareholder has already returned the Original Form of Proxy in accordance with the instructions printed thereon, he/she/it should note that:

- (i) If no revised form of proxy is returned by the Shareholder, the Original Form of Proxy will be treated as a valid form of proxy lodged by the Shareholder if duly completed. The proxy appointed under the Original Form of Proxy will also be entitled to vote in accordance with the instructions previously given by the Shareholder or at his/her/its discretion (if no such instructions are given) on any resolution properly put to the AGM (including the additional proposed resolutions as set out in this supplemental circular and the supplemental notice of the AGM).
- (ii) If the revised form of proxy is returned by the Shareholder at or before the Closing Time in accordance with the instructions printed thereon, the revised form of proxy will be treated as a valid form of proxy lodged by the Shareholder if duly completed, and will revoke and supersede the Original Form of Proxy previously lodged by him/her/it.

LETTER FROM THE BOARD

- (iii) If the revised form of proxy is returned by the Shareholder after the Closing Time, the revised form of proxy will be deemed invalid. It will not revoke the Original Form of Proxy previously lodged by the Shareholder. The Original Form of Proxy will be treated as a valid form of proxy lodged by the Shareholder if duly completed. The proxy appointed under the Original Form of Proxy will also be entitled to vote in accordance with the instructions previously given by the Shareholder or at his/her/ its discretion (if no such instructions are given) on any resolution properly put to the AGM (including the additional proposed resolutions as set out in this supplemental circular and the supplemental notice of the AGM).

As required under the Listing Rules, all resolutions put to vote at the AGM will be decided by way of poll.

By order of the Board
Town Health International Medical Group Limited
Kwok Chung On
Company Secretary

APPENDIX BIOGRAPHICAL DETAILS OF THE NOMINATED DIRECTORS

Below are the biographical details of each of Dr. Wong Chi Kit Nelson, Ms. Yao Yuan and Kong Peng which were reproduced from the Nomination Notice and has not been independently verified by the Company or the Board:

(A) BIOGRAPHICAL DETAILS OF DR. WONG CHI KIT NELSON

Dr. WONG, Chi Kit Nelson, aged 70, was formerly an Executive Director of the Company from 28th June 2022 to 1st Jan 2024 and its Chief Executive from 20th June 2022 to 1st Jan 2024. He is the Chief Executive of Dr. Vio & Partners Limited, a non-wholly owned subsidiary of the Company.

Dr. Wong received his medical education at the University of London on a British Council Scholarship. In 1981, he passed his Diploma of Membership of the Royal Colleges of Physicians of the United Kingdom, MRCP (UK). He subsequently embarked on a self-study course in insurance operations and was awarded the Fellowship Diploma of the Life Management Institute (FLMI) with Distinction in 1987. He was formerly a part-time Consultant of several major insurers.

Dr. Wong is a serial entrepreneur, having built and sold 3 successful medical firms to 3 listed companies. In 1982, he co-founded Allied Medical Practices Guild with an innovative structure and a disruptive business model. Dr. Wong pioneered a unique intranet Point-of-Sale system to facilitate front-line eligibility checking and back-office Electronic Data Interchange in 1998, before e-commerce became fashionable. He has also developed an effective pharmacy benefit management system. He tried to retire in 2003, only to be lured out of retirement in 2005 to take the helm at Dr. Vio & Partners Limited,

Under the leadership of Dr. Nelson Wong, the Vio network has become one of the largest corporate medical scheme operators in Hong Kong and it is the most consistently profitable unit of the Company in Hong Kong. Vio is also the only medical network with ISO 9001:2015 Quality Management System certification. Dr. Nelson Wong has worked in this field for over 40 years and is the only doctor who has personal experience of managing all the large medical networks in Hong Kong either directly or indirectly under corporate clients' instruction as a third-party administrator.

Widely recognised as an expert in corporate medical schemes, he had served on relevant professional committees and written an Editorial on Contract Medicine in the Hong Kong Medical Association Newsletter. He was also the invited author of a book chapter on Managed Care in The University of Hong Kong position book on Hong Kong's Health System in 2006. He served on the Working Group on Primary Care under the HKSAR Government's Health and Medical Development Advisory Committee from 2008-2016. He is a Vice-Chairman of the Business and Professionals Federation of Hong Kong. Above all, he is a respected and well-liked leader with colleagues loyally following him for decades.

APPENDIX BIOGRAPHICAL DETAILS OF THE NOMINATED DIRECTORS

As at the date of this Notice, Dr. Wong is the beneficial owner of 5.7% of Dr. Vio & Partners Ltd. through his ownership of Crown Glory Assets Ltd., of which he is a Director. He is also a Director of several subsidiaries of the Company, namely: Dr. Vio & Partners Limited, Bright Elite Investments Limited, Ever Ease Holdings Limited, Glorious Jade Limited, Goal Bright Investments Limited, Good Chance Limited, Oriental Sharp Holdings Limited, Standard Glory International Limited, Town Health Medical Network Services Limited, Version System International Limited, World Joy Limited. Dr. Wong is a Director of 3 companies operating fertility clinics and IVF laboratories, namely: The Women's Clinic Group Ltd., Reproductive HealthCare Ltd. and Victory "ART" Laboratory Ltd.

Dr. Wong was a director of Ringbell Company Limited ("**Ringbell**"), a private company incorporated in Hong Kong and dissolved by deregistration on 15 August 2003 under section 29 IAA of Chapter 32. Ringbell was inactive before deregistration. As confirmed by Dr. Wong, Ringbell was solvent prior to its dissolution.

Save as disclosed above, as at the date of this Notice, Dr. Wong does not hold (i) any other positions with the Company or other members of the Group; and (ii) any other major appointment and professional qualification. Save as disclosed above, Dr. Wong (i) did not hold any directorships in the last three years in any public companies the securities of which are listed on any securities market in Hong Kong or overseas; (ii) does not have any relationship with any Directors, senior management, substantial or controlling Shareholders (having the meanings ascribed to them in the Listing Rules); and (iii) is not interested in any Shares within the meaning of Part XV of the SFO.

Save as disclosed above, there is no further information to be disclosed pursuant to the requirements of Rules 13.51 (2)(h) to (v) of the Listing Rules and there are no other matters relating to the appointment of Dr. Wong as a Director that need to be brought to the attention of the Shareholders.

APPENDIX BIOGRAPHICAL DETAILS OF THE NOMINATED DIRECTORS

(B) BIOGRAPHICAL DETAILS OF MS. YAO YUAN

Ms. YAO, Yuan, aged 40, was appointed as an executive Director on 28 June 2022.

Ms. Yao obtained a degree of Bachelor of Science in Business Administration from Troy University in May 2006, and a degree of Master of Corporate Governance from Hong Kong Metropolitan University in November 2021. Ms. Yao has more than 18 years' of experience in management, business development and investor relations. Ms. Yao has served the Company in different capacities for over 13 years, leads the medical and dental subsidiary. She has efficiently and patiently dealt with some independent minded professionals, stabilized and expanded the medical team and spearheaded the remarkable return to profitability from multimillion dollars' loss of yesteryears to millions of profits in the first half of 2023. She also has extensive knowledge of the Company's operations, and her mainland background has helped the Company established communication channels and collaborations with provincial and municipal governments and large institutions in Mainland China, opening up new opportunities for cross-border medical businesses and greatly raised the Company's profile in the Mainland China market, particularly in the Greater Bay Area, building a solid foundation for the Company's prospects in the future integrated Greater Bay Area. Ms. Yao was appointed as Executive Director of the Company from 28th June 2022 to 1st Jan 2024. Ms. Yao remains as the General Manager of one of key operating subsidiary of the Company.

Save as disclosed above, as at the date of this Notice, Ms. Yao does not hold (i) any other positions with the Company or other members of the Group; and (ii) any other major appointment and professional qualification. Save as disclosed above, Ms, Yao (i) did not hold any directorships in the last three years in any public companies the securities of which are listed on any securities market in Hong Kong or overseas; (ii) does not have any relationship with any Directors, senior management, substantial or controlling Shareholders (having the meanings ascribed to them in the Listing Rules); and (iii) is not interested in any Shares within the meaning of Part XV of the SFO.

As at the date of this Notice, Ms. Yao has interests in 120,000 Shares within the meaning of Part XV of the SFC. Save as disclosed above, there is no further information to be disclosed pursuant to the requirements of Rules 13.51(2)(h) to (v) of the Listing Rules and there are no other matters relating to the appointment of Ms. Yao as a Director that need to be brought to the attention of the Shareholders.

APPENDIX BIOGRAPHICAL DETAILS OF THE NOMINATED DIRECTORS

(C) BIOGRAPHICAL DETAILS OF MR. KONG PENG

Mr. KONG, Peng, aged 45, his educational background is extensive and directly relevant to the scope of services required for this appointment. His Bachelor of Science, Diploma in Dental Therapy, Post-Graduate Diploma of Public Health, and three master's degrees in public health, Health Services Management, and MBA demonstrate a strong foundation in healthcare, public health, and management.

With over 15 years of management experience in the healthcare field, including roles as Chief Executive Officer and Chief Operating Officer of major healthcare groups in Hong Kong, Mr. Kong brings a wealth of leadership skills to the table. His experience in leading Wraparound Healthcare Limited, a platform for over 10,000 healthcare professionals, showcases his ability to manage large-scale projects and initiatives effectively.

As the founder and Chairman of Wraparound Healthcare Limited, Mr. Kong has demonstrated entrepreneurial spirit and innovative thinking. His involvement in "Uberizing" healthcare and implementing large-scale COVID-19 screenings and vaccinations underscores his ability to think outside the box and implement impactful solutions.

Mr. Kong's track record of advising healthcare groups and government agencies on business transformation, strategic planning, and operational improvement is highly relevant to the objectives of the landscape assessment project. His role in advising the government on Primary Care Reform, including standardization of services fees, IT system requirements, and public health strategies, showcases his strategic planning expertise.

With experience in various healthcare organizations, including specialist healthcare providers, medical groups, and clinics, Mr. Kong has a deep understanding of the healthcare industry landscape. His involvement in managing healthcare networks, third-party administration, and medical provider relations adds valuable insights to the project.

Mr. Kong's advisory and lecturing role at The School of Public Health at the University of Hong Kong demonstrates his commitment to academic excellence and knowledge dissemination. His teaching experience adds another dimension of expertise, especially in understanding and communicating complex healthcare concepts and strategies.

In summary, Mr. Kong's comprehensive education, extensive management experience, entrepreneurial mindset, strategic acumen, industry network, and academic engagement make him an ideal candidate to lead the Company. His background aligns perfectly with the requirements of the role, ensuring a high level of expertise, leadership, and innovation throughout the appointment.

APPENDIX BIOGRAPHICAL DETAILS OF THE NOMINATED DIRECTORS

Save as disclosed above, as at the date of this Notice, Mr. Kong does not hold (i) any other positions with the Company or other members of the Group; and (ii) any other major appointment and professional qualification. Save as disclosed above, Mr. Kong (i) did not hold any directorships in the last three years in any public companies the securities of which are listed on any securities market in Hong Kong or overseas; (ii) does not have any relationship with any Directors, senior management, substantial or controlling Shareholders (having the meanings ascribed to them in the Listing Rules); and (iii) is not interested in any Shares within the meaning of Part XV of the SFO.

Save as disclosed above, there is no further information to be disclosed pursuant to the requirements of Rules 13.51(2)(h) to (v) of the Listing Rules and there are no other matters relating to the appointment of Mr. Kong as a Director that need to be brought to the attention of the Shareholders.

SUPPLEMENTAL NOTICE OF ANNUAL GENERAL MEETING



Town Health International Medical Group Limited 康健國際醫療集團有限公司

(Incorporated in the Cayman Islands and continued in Bermuda with limited liability)

(Stock Code: 3886)

SUPPLEMENTAL NOTICE OF ANNUAL GENERAL MEETING

Reference is made to the notice of annual general meeting of Town Health International Medical Group Limited (“**Company**”) dated 17 May 2024 (“**Original Notice**”), by which the Company convenes an annual general meeting to be held at 11:30 a.m. on Wednesday, 12 June 2024 at 1st Floor, Town Health Technology Centre, 10-12 Yuen Shun Circuit, Siu Lek Yuen, Shatin, New Territories, Hong Kong (“**Meeting**”) and this supplemental notice shall be read together with the Original Notice.

SUPPLEMENTAL NOTICE IS HEREBY GIVEN that in addition to the resolutions set out in the Original Notice, the following ordinary resolutions will be considered and, if thought fit, approved by the shareholders of the Company (“**Shareholders**”) at the Meeting:

ORDINARY RESOLUTIONS

9. “THAT Dr. Wong Chi Kit Nelson be appointed as a director of the Company.”
10. “THAT Ms. Yao Yuan be appointed as a director of the Company.”
11. “THAT Mr. Kong Peng be appointed as a director of the Company.”

By order of the Board

Town Health International Medical Group Limited

Kwok Chung On

Company Secretary

Hong Kong, 28 May 2024

SUPPLEMENTAL NOTICE OF ANNUAL GENERAL MEETING

Registered office:

Clarendon House
2 Church Street
Hamilton HM 11
Bermuda

*Head office and principal place
of business in Hong Kong:*

6th Floor
Town Health Technology Centre
10-12 Yuen Shun Circuit
Siu Lek Yuen
Shatin, New Territories
Hong Kong

Notes:

1. A Shareholder entitled to attend and vote at the Meeting convened by the above notice is entitled to appoint one or more proxy to attend and, subject to the provisions of the bye-laws of the Company, to vote on his/her/its behalf. A proxy need not be a Shareholder but must be present in person at the Meeting to represent the Shareholder. If more than one proxy is so appointed, the appointment shall specify the number and class of shares in respect of which each such proxy is so appointed.
2. To ascertain the entitlement of the Shareholders to attend and vote at the Meeting convened by the above notice, the register of members of the Company will be closed from Thursday, 6 June 2024 to Wednesday, 12 June 2024, both days inclusive, during which no transfer of shares of the Company (“**Shares**”) will be effected. In order to qualify for the entitlement to attend and vote at the Meeting, all transfers of Shares accompanied by the relevant share certificates must be lodged with the Company’s branch share registrar and transfer office in Hong Kong, Tricor Tengis Limited at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong, by 4:30 p.m. on Wednesday, 5 June 2024.
3. Since the original form of proxy which was despatched by the Company to the Shareholders on 17 May 2024 (“**Original Form of Proxy**”) and sent together with the Original Notice does not contain the proposed resolutions set out in this supplemental notice, a revised form of proxy (“**Revised Form of Proxy**”) has been prepared and is enclosed with the supplemental circular of the Company dated 28 May 2024 (“**Supplemental Circular**”) of which this supplemental notice forms part.
4. To be valid, the Revised Form of Proxy, together with the power of attorney or other authority (if any) under which it is signed (or a notarially certified copy thereof), must be deposited at the office of the Company’s branch share registrar and transfer office in Hong Kong, Tricor Tengis Limited at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong, by 11:30 a.m. on Monday, 10 June 2024 or not less than 48 hours before the time appointed for holding the adjourned Meeting (“**Closing Time**”).
5. Completion and return of an instrument appointing a proxy will not preclude a Shareholder from attending and voting in person at the Meeting or any adjournment thereof and in such event the instrument appointing a proxy shall be deemed to be revoked.
6. If a Shareholder has not yet returned the Original Form of Proxy in accordance with the instructions printed thereon, and wishes to appoint a proxy to attend the Meeting on his/her/its behalf, he/she/it is required to submit the Revised Form of Proxy. In this case, the Shareholder shall not submit the Original Form of Proxy.

SUPPLEMENTAL NOTICE OF ANNUAL GENERAL MEETING

7. If a Shareholder has already returned the Original Form of Proxy in accordance with the instructions printed thereon, he/she/it should note that:
- (i) If no Revised Form of Proxy is returned by the Shareholder, the Original Form of Proxy will be treated as a valid form of proxy lodged by the Shareholder if duly completed. The proxy appointed under the Original Form of Proxy will also be entitled to vote in accordance with the instructions previously given by the Shareholder or at his/her/its discretion (if no such instructions are given) on any resolution properly put to the Meeting (including the additional proposed resolutions as set out in the Supplemental Circular and this supplemental notice).
 - (ii) If the Revised Form of Proxy is returned by the Shareholder at or before the Closing Time in accordance with the instructions printed thereon, the Revised Form of Proxy will be treated as a valid form of proxy lodged by the Shareholder if duly completed, and will revoke and supersede the Original Form of Proxy previously lodged by him/her/it.
 - (iii) If the Revised Form of Proxy is returned by the Shareholder after the Closing Time, the Revised Form of Proxy will be deemed invalid. It will not revoke the Original Form of Proxy previously lodged by the Shareholder. The Original Form of Proxy will be treated as a valid form of proxy lodged by the Shareholder if duly completed. The proxy appointed under the Original Form of Proxy will also be entitled to vote in accordance with the instructions previously given by the Shareholder or at his/her/its discretion (if no such instructions are given) on any resolution properly put to the Meeting (including the additional proposed resolutions as set out in the Supplemental Circular and this supplemental notice).
8. As required under the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, the above resolutions will be decided by way of poll.
9. References to time and dates in this supplemental notice are to Hong Kong time and dates.